MUC6 and colorectal carcinoma: In conclusion, we found loss of MUC2 expression to be a predictor of adverse outcome, while gain of aberrant MUC5AC and particularly MUC6 expression was associated with favorable outcome in CRC, especially in intermediate stages II and III.